Autres langues Arcus Biosciences, Inc.

Actions

RCUS

US03969F1093

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 17:15:30 05/08/2026			Varia. 5j.	Varia. 1 janv.
28,52 ^USD	-0,97%		+8,20%	+20,10%

03/08	ARCUS BIOSCIENCES, INC. : BofA Securities à l'achat	ZM
22/07	Arcus Biosciences et Summit Therapeutics concluent une collaboration d'essai clinique pour évaluer le casdatifan associé à l'ivonescimab dans le cancer du rein	CI

Autres langues

27/07	Arcus Biosciences Announces New Employment Inducement Grants
22/07	Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
22/07	Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
21/07	Arcus Biosciences : to Host Conference Call to Discuss Second-Quarter 2026 Financi...
21/07	Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
13/07	Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing
09/07	Arcus Biosciences Announces New Employment Inducement Grants
01/07	New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
24/06	Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing
24/06	Arcus Biosciences Announces New Employment Inducement Grants
09/06	Arcus Biosciences Announces New Employment Inducement Grants
04/06	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer
03/06	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
03/06	Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial
03/06	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
03/06	Arcus Biosciences, Inc. and Bristol Myers Squibb Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer
26/05	Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
06/05	Arcus Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
05/05	Arcus Biosciences Q1 Loss Narrows, Revenue Falls
05/05	Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88
05/05	Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q1 Revenue $17.0M, vs. FactSet Est of $29.5M
05/05	Arcus Biosciences : Reports First-Quarter 2026 Financial Results and Provides a Pi...
05/05	Arcus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026